Breakfast News: Gilead Bets Big on Its Next Phase

Breakfast News: Gilead Bets Big on Its Next Phase

March 24, 2026

Source: Image created by Jester AI.

1. Gilead Buys Ouro to Boost Portfolio

Gilead Sciences (GILD +0.10%) was little changed ahead of the opening bell after news broke of a $2.18 billion deal to buy Ouro Medicines, in a bid to secure assets to bolster its growing inflammation portfolio.

• “This acquisition underscores our commitment to advancing transformative therapies”: Chief medical officer Dietmar Berger talked up the deal, with Ouro’s key drug gamgertamig already in the FDA fast-track process. The Stock Advisor recommendation by Team Rule Breakers is also in talks with Galapagos (GLPG 0.28%) for a potential research collaboration with Ouro’s assets.
• “Gilead is looking like a reasonably priced healthcare stock with room for plenty of further growth”: Discussing the company last month, Fool contributing analyst Dan Caplinger said it “has had a great start to 2026,” with “product sales projected to approach or exceed the $30 billion this year.”

2. Tesla Ends 14-Month Europe Sales Slump

Tesla (TSLA +3.53%) recorded its first increase in European monthly sales in over a year, with new-car registrations growing almost 12%, providing a positive sign it’s able to compete with Chinese EV alternatives.

• **Last recorded growth in Europe was in December 2024: **The data, released by the European Automobile Manufacturers’ Association, comes off the back of data last week showing Tesla’s retail sales in China jumped over 42% year over year. Tesla is recommended by both Team Hidden Gems and Team Rule Breakers, with the stock beating the S&P 500 by 112% since the Hidden Gems rec in April 2024.
• European EV market subset grew almost 16% last month: Battery electric vehicles (cars powered exclusively by batteries) experienced high demand. Tesla can take confidence from the overall trend in the EV space, with registrations of plug-in-hybrid models growing by 33%. However, competitor BYD (BYDDY +3.09%) saw registrations almost triple in February.

3. Broadcom Warns of Growing AI Bottlenecks

Rule Breakers rec** Broadcom** (AVGO +4.08%) cautioned on supply chain constraints in the AI infrastructure space, providing potential headaches for the sector, as high demand for AI chips triggers capacity constraints at key manufacturers like Taiwan Semiconductor (TSM +2.88%).

• “They will be increasing the capacity to 2027, but that has become a bottleneck, or that has kind ‌of choked the supply chain ⁠in 2026”: Speaking about TSM, Broadcom’s director of product marketing Natarajan Ramachandran said, until recently, capacity limits for chips was seen as infinite.
• Capacity constraints observed in other areas of tech supply chains: Ramachandran pointed to printed circuit boards (PCBs) and lasers as two other notable areas experiencing production pressures, ultimately starting to contribute to longer lead times from suppliers to end users.

4. Your Take

What’s on your watchlist right now? Do impending market corrections change how you think about adding new positions?

Discuss with friends and family, or become a member to hear what your fellow Fools are saying!